ClinicalTrials.gg

Program

tarlatamab

Its studies are mostly in Small Cell Lung Carcinoma · Neoplasms · Prostatic Neoplasms, led by Amgen.

Furthest: phase 3, since Feb 7, 202313 company-led studies, 12 open or runningNext primary completion: Apr 24, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amgen1312 open or runningphase 3since Feb 7, 2023Oct 5, 2017Apr 24, 2027phase 1 · NCT06598306

Also a collaborator on its studies: AstraZeneca and BeOne Medicines.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 2 studies since Oct 5, 2017.

  1. Sep 17, 2021Phase 2 study in Small Cell Lung CarcinomaNCT05060016 · 222 enrolled · United States, Austria, Belgium and more
  2. Feb 7, 2023Phase 3 study in Small Cell Lung CarcinomaNCT05740566 · 509 enrolled · United States, Argentina, Australia and more
  3. Oct 31, 2023Phase 3 study in Small Cell Lung CarcinomaNCT06117774 · 404 enrolled · United States, Argentina, Australia and more
  4. Jan 8, 2024Phase 3 study in Small Cell Lung CarcinomaNCT06211036 · 563 enrolled · United States, Argentina, Australia and more
  5. Jul 9, 2024Phase 2 study in NeoplasmsNCT06502977 · 32 enrolled · China
  6. Sep 13, 2024Phase 1 study in Small Cell Lung CarcinomaNCT06598306 · 220 planned · United States, Australia, Belgium and more
  7. Dec 17, 2024Phase 2 study in Small Cell Lung CarcinomaNCT06745323 · 252 enrolled · United States, Argentina, Australia and more
  8. Mar 21, 2025Phase 1 study in Small Cell Lung CarcinomaNCT06898957 · 29 enrolled · United States, Canada, China and more
  9. May 27, 2025Phase 3 study in Small Cell Lung CarcinomaNCT07005128 · 350 enrolled · United States, Argentina, Australia and more
  10. Apr 9, 2026Phase 1 study in Small Cell Lung CarcinomaNCT07531095 · 160 planned · United States, Australia, Belgium and more
  11. Aug 12, 2026Phase 3 study in Small Cell Lung CarcinomaNCT07778316 · 400 planned · United States, Australia, China and more
  12. Oct 6, 2026Primary completion moved from 2029-05-10 to 2029-08-10Date moved laterphase 2 · +3 months · NCT06745323
  13. Nov 4, 2026Primary completion moved from 2026-12-31 to 2027-12-31Date moved laterphase 1 · +12 months · NCT03319940
  14. Nov 6, 2026Primary completion moved from 2027-07-05 to 2030-04-02Date moved laterphase 3 · +33 months · NCT06211036

Ahead

  1. Apr 24, 2027Primary completion: phase 1 study in Small Cell Lung CarcinomaNCT06598306
  2. Sep 24, 2027Primary completion: phase 3 study in Small Cell Lung CarcinomaNCT07778316
  3. Dec 30, 2027Primary completion: phase 2 study in Small Cell Lung CarcinomaNCT05060016
  4. Dec 31, 2027Primary completion: phase 1 study in Small Cell Lung CarcinomaNCT03319940

TargetBeta

CD3E →DLL3 →read by rule
“A bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) delta-like protein 3 (DLL3) ”NCIt, by rule
“T cell surface glycoprotein CD3 binding agent; Delta-like protein 3 binding agent”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
AlveltamigruleSuzhou Zelgen Biopharmaceuticalsphase 311
obrixtamigBoehringer Ingelheimphase 311
gocatamigMerckphase 34
SHR-7787Jiangsu HengRui Medicinephase 21
clesitamigHoffmann-La Rochephase 12
HLX3901Fosun Pharmaphase 11

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07778316Small Cell Lung Carcinoma · United States, Australia, China and more3RecruitingSep 24, 2027400
NCT07531095Small Cell Lung Carcinoma · United States, Australia, Belgium and more1RecruitingMay 21, 2028160
NCT07005128Small Cell Lung Carcinoma · United States, Argentina, Australia and more3Active, not recruitingJan 4, 2029350
NCT06898957Small Cell Lung Carcinoma · United States, Canada, China and more1Active, not recruitingJun 23, 203129
NCT06745323Small Cell Lung Carcinoma · United States, Argentina, Australia and more2Active, not recruitingAug 10, 2029252
NCT06598306Small Cell Lung Carcinoma · United States, Australia, Belgium and more1RecruitingApr 24, 2027220
NCT06502977Neoplasms · China2Active, not recruitingMar 28, 202532
NCT06211036Small Cell Lung Carcinoma · United States, Argentina, Australia and more3Active, not recruitingApr 2, 2030563
NCT06117774Small Cell Lung Carcinoma · United States, Argentina, Australia and more3Active, not recruitingApr 20, 2030404
NCT05740566Small Cell Lung Carcinoma · United States, Argentina, Australia and more3Active, not recruitingJan 29, 2025509
NCT05060016Small Cell Lung Carcinoma · United States, Austria, Belgium and more2Active, not recruitingDec 30, 2027222
NCT04702737Neuroendocrine Prostate Cancer · United States, Australia, Austria and more1CompletedJul 22, 202441
NCT03319940Small Cell Lung Carcinoma · United States, Australia, Austria and more1Active, not recruitingDec 31, 2027269

How it is read

Names in the registry

  • “Tarlatamab”, 13 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.